1
|
Zambrowski O, Tavernier E, Souied EH, Desmidt T, Le Gouge A, Bellicaud D, Cochener B, Limousin N, Hommet C, Autret-Leca E, Pisella PJ, Camus V. Sleep and mood changes in advanced age after blue-blocking (yellow) intra ocular lens (IOLs) implantation during cataract surgical treatment: a randomized controlled trial. Aging Ment Health 2018; 22:1351-1356. [PMID: 28691893 DOI: 10.1080/13607863.2017.1348482] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVES Both advanced age and depression are characterized by changes in sleep patterns. Light exposure is one of the main synchronizers of circadian cycles and influences sleep by inhibiting melatonin secretion, which is mostly sensitive to light of low wavelengths (blue). Blue-blocking (yellow) intraocular lenses (IOLs) have supplanted the usual UV-blocking (clear) IOLs during cataract surgery to prevent age-related macular degeneration, however, the impact of yellow IOLs on sleep and mood is unclear. The purpose of this study was to compare the effects of yellow and clear IOLs on sleep and mood in aged patients undergoing bilateral cataract surgery. METHODS A randomized controlled superiority study was conducted within three ophthalmic surgical wards in France. A total of 204 subjects (mean age 76.2 ± 7.5 years) were randomized into yellow or clear IOLs groups. Patients completed a sleep diary, the pictorial sleepiness scale and the Beck Depression Inventory (BDI) one week before and eight weeks after the last surgical procedure. RESULTS According to an Intent To Treat (ITT) analysis, no significant difference was found between yellow and clear IOLs groups regarding sleep time, sleep latency, total sleep duration, quality of sleep and BDI scores. The rate of patients whose BDI score increased at the cutoff score of ≥5 after surgery was significantly higher in the yellow IOL group (n = 11, 13.1%) compared with the clear IOL group (n = 4; 4.7%); p = 0.02. CONCLUSIONS Using yellow IOLs for cataract surgery doesn't significantly impact sleep but may induce mood changes in aging.
Collapse
Affiliation(s)
- Olivia Zambrowski
- a CHRU de Tours , Tours , France.,b Centre Hospitalier Intercommunal de Créteil , Créteil , France
| | | | - Eric H Souied
- b Centre Hospitalier Intercommunal de Créteil , Créteil , France
| | | | | | | | | | | | - Caroline Hommet
- a CHRU de Tours , Tours , France.,d Université François Rabelais de Tours , Tours , France.,f INSERM U930 , Tours , France
| | - Elisabeth Autret-Leca
- a CHRU de Tours , Tours , France.,d Université François Rabelais de Tours , Tours , France
| | - Pierre-Jean Pisella
- a CHRU de Tours , Tours , France.,d Université François Rabelais de Tours , Tours , France
| | - Vincent Camus
- a CHRU de Tours , Tours , France.,c CIC INSERM 1415 , Tours , France.,d Université François Rabelais de Tours , Tours , France.,f INSERM U930 , Tours , France
| |
Collapse
|
2
|
Marchand MS, Autret-Leca E, Bourdais E, Jonville-Béra AP. [Photoallergy to piroxicam: what should be contraindicates?]. Therapie 2013; 68:57-8. [PMID: 23484664 DOI: 10.2515/therapie/2013009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Accepted: 12/03/2012] [Indexed: 11/20/2022]
|
3
|
Marchand MS, Jonville-Béra AP, Autret-Leca E. Troubles psychiatriques associés au montélukast : données de la base nationale de pharmacovigilance. Arch Pediatr 2013; 20:269-73. [DOI: 10.1016/j.arcped.2012.12.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Revised: 11/11/2012] [Accepted: 12/14/2012] [Indexed: 10/26/2022]
|
4
|
Tarfaoui N, Autret-Leca E, Mazjoub S, Cissoko H, Jonville-Béra AP. Toxicité rétinienne de l’hydroxychloroquine chez le nouveau-né exposé in utero. Therapie 2013; 68:43-7. [DOI: 10.2515/therapie/2013003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Accepted: 12/17/1900] [Indexed: 11/20/2022]
|
5
|
Autret-Leca E, Jonville-Béra AP. Info-médicaments. Arch Pediatr 2012. [DOI: 10.1016/j.arcped.2012.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Autret-Leca E, Jonville-Béra AP. Info-médicaments : spéciale néonatalogie. Arch Pediatr 2012; 19:999-1001. [DOI: 10.1016/j.arcped.2012.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2012] [Accepted: 06/14/2012] [Indexed: 10/26/2022]
|
7
|
Autret-Leca E, Marchand MS, Cissoko H, Beau-Salinas F, Jonville-Béra AP. Pharmacovigilance en pédiatrie. Arch Pediatr 2012; 19:848-55. [DOI: 10.1016/j.arcped.2012.05.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2011] [Revised: 04/19/2012] [Accepted: 05/25/2012] [Indexed: 10/26/2022]
|
8
|
Autret-Leca E, Jonville-Béra AP. Info-médicaments. Arch Pediatr 2012; 19:765-71. [DOI: 10.1016/j.arcped.2012.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2012] [Accepted: 04/18/2012] [Indexed: 11/29/2022]
|
9
|
Autret-Leca E, Jonville-Béra AP. Infos médicaments. Arch Pediatr 2012. [DOI: 10.1016/j.arcped.2012.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
10
|
Autret-Leca E, Jonville-Béra AP. Infos médicaments. Arch Pediatr 2012. [DOI: 10.1016/j.arcped.2011.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Abstract
BACKGROUND Many studies have described the prescribing of drugs to pregnant women, but only very few have data concerning the periconceptional period specifically. AIM The aim of the study was to evaluate the incidence of exposure to teratogenic drugs during early pregnancy and to determine whether a safer drug exists. METHODS In a French health insurances database, we analyzed drugs prescribed during the period starting 1 month before and ending 2 months after the beginning of pregnancy between 1 January 2006 and 31 December 2007. Based on the Summary of Product Characteristics (SPC), drugs we considered were those 'contraindicated', 'not recommended', 'to be avoided', and 'possible' for use during the first trimester of pregnancy. For drugs 'contraindicated', we established if there were alternatives with similar efficacy for the mother and lower risk for the fetus. RESULTS Over a period of 2.25 years, 8754 drugs were prescribed to 1793 women starting 1 month prior to and ending 2 months after conception. Among these drugs, 20 (0.2%) were 'contraindicated', 195 (2.2%) were 'not recommended', and 1209 (13.8%) were 'to be avoided' during the first trimester of pregnancy. Twenty (1.1%) women received at least one drug that was 'contraindicated' during the first trimester, 171 (9.5%) received a drug that was 'not recommended' and 768 (42.8%) received a drug that was 'to be avoided'. At least one possible alternative was available for all except one 'contraindicated' drug. CONCLUSIONS During the highest teratogenic risk period, 1.1% of women received a contraindicated drug, despite existence of a safer alternative drug. This may be partly accounted for by physicians not being aware of the pregnancy at the time the drug was administered and could be reduced by adding a section entitled 'women of child-bearing potential' to the SPC.
Collapse
Affiliation(s)
- Elisabeth Autret-Leca
- CHRU de Tours, Service de Pharmacologie Clinique, Centre Rgional de Pharmacovigilance et dInformation sur le Mdicament, Tours, France.
| | | | | | | | | | | |
Collapse
|
12
|
|
13
|
Jonville-Bera AP, Autret-Leca E. [Adverse drug reactions of strontium ranelate(Protelos(®) in France]. Presse Med 2011; 40:e453-62. [PMID: 21885232 DOI: 10.1016/j.lpm.2011.07.010] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2011] [Revised: 07/19/2011] [Accepted: 07/22/2011] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE Study of side effects (SE) associated with strontium ranelate required by the French Drug agency (Afssaps). METHOD SE associated with strontium ranelate and spontaneously reported until March 2009 to the manufacturer or to the French Regional Pharmacovigilance Centers and the periodic safety reports have been analyzed. Utilisation and sales data have been obtained from the manufacturer. RESULTS During the 3 years of the study, 844 SE have been reported in France in patients treated with strontium ranelate. The 199 severe SE are cardiovascular (52%), cutaneous (26%), hepatodigestive (6%), neurological (5%), haematological (3%), osteomuscular (3%) and various (3%). Venous thromboembolic events (VTEE) are the most frequent cardiovascular SE (93/104) with an incidence of 1/31,052 months of treatment. At least one VTEE risk factor is present in 26 (28%) patients. DRESS syndrome which median delay of advent is 35 days is the most frequent cutaneous SE (19/51 SE) with an incidence of 1/13,725 months of treatment. The 14 severe hepatodigestive SE are hepatitis (n=5), pancreatitis (n=2) and various others SE (n=7). The 10 severe neurological SE are confusion/amnesia (n=5), convulsions (n=4) and parenthesis (n=1). The seven severe haematological SE are pancytopenia (n=5), erythroblastopenia (n=1) and thrombocytopenic purpura (n=1). Among the seven deaths, only three (two pulmonary embolisms, one DRESS syndrome) are attributable to strontium ranelate. Apart from the severe SE, 685 SE have also been reported because strontium ranelate was the only drug with an imputability "suspect". DISCUSSION Anti-fractural effect of strontium ranelate is at least as equal as those of bisphosphonates. Its usual SE are benign but two severe risks of strontium ranelate i.e. VTEE and DRESS syndrome are confirmed. The profile of tolerability, different from the one of bisphosphonates makes strontium ranelate as an alternative when bisphosphonates are not recommended or contraindicated (renal insufficiency for example). CONCLUSION If DRESS syndrome is unpredictable, the one of VTEE could be reduced by a strontium ranelate contraindication for patients with a history of VTEE and by stopping the drug if a new VTEE risk situation happens.
Collapse
Affiliation(s)
- Annie-Pierre Jonville-Bera
- CHRU de Tours, service de pharmacologie clinique, centre régional de pharmacovigilance et d'information sur le médicament, 37044 Tours, France
| | | |
Collapse
|
14
|
Grimaldi-Bensouda L, Rossignol M, Danchin N, Steg PG, Bessede G, Ovize M, Cottin Y, Autret-Leca E, Benichou J, Abenhaim L. Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs. Heart 2011; 97:1834-40. [DOI: 10.1136/hrt.2011.222448] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
15
|
|
16
|
Autret-Leca E, Grimaldi-Bensouda L, Daubin C, Poggi P, Collignon AE, Jonville-Béra AP. Heptavalent pneumococcal conjugate vaccine (PCV7): French survey of serious adverse reactions. Therapie 2011; 66:81-6. [PMID: 21466782 DOI: 10.2515/therapie/2011006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2010] [Accepted: 07/29/2010] [Indexed: 11/20/2022]
Abstract
PURPOSE Previous study did not reveal any particular heptavalent pneumococcal conjugate vaccine (PCV7) related risk. However, french drugs agency (Afssaps) requested the continuation of its surveillance. METHODS All serious PCV7-related adverse drug reactions spontaneously reported between October 1, 2004 and December 31, 2007 to the French pharmacovigilance centers or to Wyeth Pharmaceutical France were included. Vaccine failure was defined as an invasive pneumococcal infection due to vaccine serotype which occurs at least 15 days after the third dose of vaccine. Incidence rates were estimated according to the doses number except for vaccine failure estimated according to the vaccinated children number. RESULTS During the 39-month follow-up period, 154 serious adverse drug reactions were spontaneously reported: convulsions (17%), fever (13%), hypotonia (10%), sudden death (7%) and thrombopenic purpura (6%). Evolution was recovery in 72% of cases. PCV7 was the only suspect medication in 28% of cases. The median age was 4 months (range 1-108), and the children's sex was male in 53%. The adverse drug reaction recurred after a subsequent injection in six cases. Among the 24 pneumococcal infections PCV7 failure was certain in 4 cases. The incidences of serious adverse drug reactions did not differ from our previous survey, except the incidence of thrombopenic purpura and of PCV7 failure which seems to be increasing. CONCLUSIONS This new study confirms the risk of vascular purpura, raises the thrombopenic purpura issue, and the emergence of PCV7 failures which will need a strict monitoring of the future 13 valences vaccine.
Collapse
Affiliation(s)
- Elisabeth Autret-Leca
- Centre Régional de Pharmacovigilance et d'Information sur le Médicament, Tours, France
| | | | | | | | | | | |
Collapse
|
17
|
|
18
|
Autret-Leca E. Infos médicaments. Arch Pediatr 2011; 18:103-10. [DOI: 10.1016/j.arcped.2010.09.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Accepted: 09/27/2010] [Indexed: 11/24/2022]
|
19
|
Jonville-Bera AP, Guilmot JL, Aspe G, Autret-Leca E, Magnant J. Is exogenous administration of IL-1ra (anakinra) likely to induce severe depression? Eur J Clin Pharmacol 2010; 67:213-4. [DOI: 10.1007/s00228-010-0915-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2010] [Accepted: 09/27/2010] [Indexed: 11/30/2022]
|
20
|
Autret-Leca E. [Drugs news]. Arch Pediatr 2010; 17:1596-603. [PMID: 20719481 DOI: 10.1016/j.arcped.2010.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2010] [Accepted: 07/06/2010] [Indexed: 11/17/2022]
Affiliation(s)
- E Autret-Leca
- Department of Pharmacology, Hospital Bretonneau, CHRU of Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.
| |
Collapse
|
21
|
Autret-Leca E, Kreft-Jais C, Elefant E, Cissoko H, Darrouzain F, Grimaldi-Bensouda L, Attia S, Jonville-Béra AP. Isotretinoin Exposure during Pregnancy. Drug Saf 2010; 33:659-65. [DOI: 10.2165/11536250-000000000-00000] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
22
|
Autret-Leca E. [Most innovative drugs labelled during the last years in paediatrics: does the paediatrician have the tools for their identification?]. Arch Pediatr 2010; 17:1237-42. [PMID: 20615673 DOI: 10.1016/j.arcped.2010.05.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2009] [Revised: 04/13/2010] [Accepted: 05/06/2010] [Indexed: 11/18/2022]
Abstract
When a new drug is labelled, before deciding its integration in the therapeutic strategy, the doctor has to know the degree of innovation of the drug, i.e. its actual benefit and the improvement of actual benefit, also called added value over other available drugs. For each new medicine in France, after drug approval by the French Drug Agency, the French National Authority for Health thought its "Commission de transparence" (Transparency Commission) issues an opinion about the degree of innovation of the drug, which is independent of the marketing authorization. The added value over other available drugs is quantified by five levels of improvement: level I, major progress to level V, no progress. The complete opinion of the Transparency Commission and its synthesis (one page) is online http://www.has-sante.fr/. Between 2006 and 2008, no paediatric drug has obtained a level I of improvement (major progress), ten have obtained a level II (significant progress), 11 a level III (moderate progress), 12 a level IV (minor progress) and for 38 drugs, no progress has been retained. The need to know and to follow therapeutic recommendations is the evidence based medicine. The opinions of the Transparency Commission are one of those recommendations.
Collapse
Affiliation(s)
- E Autret-Leca
- Service de pharmacologie clinique, centre régional de pharmacovigilance et d'information sur le médicament, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.
| |
Collapse
|
23
|
|
24
|
Balayssac E, Autret-Leca E, Jonville-Béra AP, Diè-Kacou H, Beau-Salinas F. [Adverse reactions of atazanavir, fosamprenavir and tipranavir in "real life"]. Therapie 2010; 65:121-8. [PMID: 20478244 DOI: 10.2515/therapie/2010003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2009] [Accepted: 12/08/2009] [Indexed: 01/11/2023]
Abstract
OBJECTIVE To precise adverse effects of atazanavir, fosamprenavir and tipranavir "in real life". METHOD Descriptive study of 3 protease inhibitor adverse effects stored in the French Bank of Pharmacovigilance. RESULTS Nineteen adverse effects having at least possible links with antiretroviral drugs studied were reported. It was essentially hepatobiliary (atazanavir: 29/59, tipranavir: 4/6) and skin (fosamprenavir: 10/20) adverse reactions. These reactions, relatively "serious" (35.1%) led to the interruption of the person (or persons) medication (s) suspected (s) in 69 folds (82.1%) and evolved to healing without sequelae in 68 folds (81%). CONCLUSION The drug side effects were for the most expected. However, their frequency and their seriously underline the interest of a post-AMM monitoring to reassess the drugs risk-benefit report.
Collapse
Affiliation(s)
- Eric Balayssac
- Centre Hospitalier Universitaire de Cocody (Abidjan), Service de Pharmacologie Clinique, Abidjan, Côte d'Ivoire.
| | | | | | | | | |
Collapse
|
25
|
Grimaldi-Bensouda L, Abenhaim L, Michaud L, Mouterde O, Jonville-Béra AP, Giraudeau B, David B, Autret-Leca E. Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study. Eur J Clin Pharmacol 2010; 66:831-7. [PMID: 20473658 DOI: 10.1007/s00228-010-0832-3] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2010] [Accepted: 04/21/2010] [Indexed: 12/15/2022]
Abstract
OBJECTIVE This population-based survey was conducted to provide a formal description of upper gastrointestinal bleeding (UGIB) in children on a nationwide basis and assess the contribution of risk factors, principally nonsteroidal anti-inflammatory drugs (NSAID). METHODS A case-crossover study of UGIB patients aged between 2 months and 16 years was conducted in France. Medical data were collected by physicians, and personal risk factors and exposure to drugs during the month preceding the onset of the bleeding was ascertained by a standardised telephone interview with parents. The odds ratios for UGIB and NSAID was assessed by comparing exposure during the 7 days preceding the date of hospitalisation and the 21st to the 28th days before that date. RESULTS A total of 177 children with UGIB were included over 2 years. Eighty-three children had taken at least one NSAID before the index date, among which 58 were ibuprofen, 26 aspirin and nine others. The adjusted odds ratio (OR) of exposure was 8.2 [95% confidence interval (CI) 2.6-26.0] for NSAIDs altogether, and this was 10.0 (95% CI 2.0-51.0) for ibuprofen and 7.3 (95% CI 0.9-59.4) for aspirin. There was no increased risk associated with NSAIDS for oesophageal lesion [OR = 1.0 [(5% CI:0.2-7.2)]. CONCLUSION The study confirms that UGIB is rare but that some cases may be avoided, as one third of the cases was attributable to exposure to NSAID at doses used for analgesic or antipyretic purposes, which may be attained with alternative therapy. The findings from this study call for more caution in prescribing NSAIDS to children.
Collapse
|
26
|
Affiliation(s)
- E Autret-Leca
- Department of pharmacology, hospital Bretonneau, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.
| |
Collapse
|
27
|
Beau-Salinas F, Jonville-Béra AP, Cissoko H, Bensouda-Grimaldi L, Autret-Leca E. Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol 2009; 66:413-7. [PMID: 20024536 DOI: 10.1007/s00228-009-0769-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2008] [Accepted: 11/23/2009] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The aim of this case/non-case study was to assess and compare the risk of drug dependence associated with different migraine-specific drugs, i.e., ergot derivatives and triptans, using the French pharmacovigilance database. METHODS Reports on drug side effects recorded in this database between January 1985 and June 2007 were analyzed, and triptans (almotriptan, eletriptan, naratriptan, sumatriptan, and zolmitriptan) as well as ergot derivatives used in acute migraine were examined. For all reports, cases were defined as those reports corresponding to "drug abuse," "physical or mental drug dependence," and "pharmacodependence," whereas "non-cases" were defined as all the remaining SED reports. The method's reliability was assessed by calculating the risk associated with a negative (amoxicillin) and a positive (benzodiazepines) control. The risk of dependence associated with each drug and control was evaluated by calculating the odds ratio (OR) with a confidence interval of 95%. RESULTS Among the 309,178 reports recorded in the database, drug dependence accounted for 0.8% (2,489) of the reports, with 10.9% (449) involving a triptan, and 9.33% (332) an ergot derivative. The risk of dependence was similar for triptans and ergot derivatives and did not differ from that of benzodiazepines. In the triptan group, the risk (odds ratio [95% CI]) ranged from 10.3 [4.8-22.3] for sumatriptan to 21.5 for eletriptan [10.1-45.6], while in the ergot derivative group, it ranged from 12 [8-17.9] for ergotamine to 20.6 [8-53] for dihydroergotamine. CONCLUSIONS These findings confirm the hypothesis that triptans and ergot derivatives are associated with an increased risk of drug dependence.
Collapse
Affiliation(s)
- Frédérique Beau-Salinas
- Department of Pharmacology, CHRU of Tours, Bretonneau Hospital, Regional Centre of Pharmacovigilance, France.
| | | | | | | | | |
Collapse
|
28
|
Autret-Leca E. [Drugs news]. Arch Pediatr 2009; 16:1587-94. [PMID: 19853424 DOI: 10.1016/j.arcped.2009.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2009] [Accepted: 09/08/2009] [Indexed: 11/16/2022]
Affiliation(s)
- E Autret-Leca
- Department of Pharmacology, Hospital Bretonneau, CHRU of Tours, 2 Boulevard Tonnelle, 37044 Tours Cedex 9, France.
| |
Collapse
|
29
|
Autret-Leca E, Bauer S, Alberti C, Jonville-Béra AP, Aujard Y, Bensouda-Grimaldi L, Baud O. Corticothérapie postnatale chez le prématuré : étude des pratiques des centres français de néonatologie en 2006. Arch Pediatr 2009; 16:999-1004. [DOI: 10.1016/j.arcped.2009.03.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2008] [Revised: 09/22/2008] [Accepted: 03/25/2009] [Indexed: 11/28/2022]
|
30
|
Bensouda-Grimaldi L, Rossignol M, Danchin N, David B, Autret-Leca E, Abenhaim L. Risque d’infarctus du myocarde (IDM) associé à une utilisation récente, chronique ou après arrêt d’AINS traditionnels. Étude cas–témoins. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.02.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
31
|
|
32
|
Legras A, Giraudeau B, Jonville-Bera AP, Camus C, François B, Runge I, Kouatchet A, Veinstein A, Tayoro J, Villers D, Autret-Leca E. A multicentre case-control study of nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock. Crit Care 2009; 13:R43. [PMID: 19331665 PMCID: PMC2689487 DOI: 10.1186/cc7766] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2008] [Revised: 02/09/2009] [Accepted: 03/30/2009] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION We aimed to establish whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during evolving bacterial community-acquired infection in adults is associated with severe sepsis or septic shock. METHODS We conducted a multicentre case-control study in eight intensive care units. Cases were all adult patients admitted for severe sepsis or septic shock due to a bacterial community-acquired infection. Control individuals were patients hospitalized with a mild community-acquired infection. Each case was matched to one control for age, presence of diabetes and site of infection. RESULTS The main outcome measures were the proportions of cases and controls exposed to NSAIDs or aspirin during the period of observation. In all, 152 matched pairs were analyzed. The use of NSAIDs or aspirin during the observation period did not differ between cases and controls (27% versus 28; odds ratio = 0.93, 95% confidence interval [CI] = 0.52 to 1.64). If aspirin was not considered or if a distinction was made between acute and chronic drug treatment, there remained no difference between groups. However, the median time to prescription of effective antibiotic therapy was longer for NSAID users (6 days, 95% CI = 3 to 7 days) than for nonusers (3 days, 95% CI = 2 to 3 days; P = 0.02). CONCLUSIONS In this study, the use of NSAIDs or aspirin during evolving bacterial infection was frequent and occurred in one-quarter of the patients with such infection. Although the use of NSAIDs by patients with severe sepsis or septic shock did not differ from their use by those with mild infection at the same infected site, we observed a longer median time to prescription of effective antibiotic therapy in NSAID users.
Collapse
Affiliation(s)
- Annick Legras
- Department of Intensive Care Unit, University Hospital of Tours, Boulevard Tonnellé, 37044 Tours, France
| | - Bruno Giraudeau
- INSERM CIC 202, François Rabelais University, Boulevard Tonnellé, 37044 Tours, France
| | - Annie-Pierre Jonville-Bera
- Department of Clinical Pharmacology and Regional Drug Monitoring Centre, University Hospital of Tours, Boulevard Tonnellé, 37044 Tours, France
| | - Christophe Camus
- Department of Intensive Care Unit, University Hospital of Rennes, Rue Henri Le Guilloux, 35033 Rennes, France
| | - Bruno François
- Department of Intensive Care Unit, CIC 0801, University Hospital of Limoges, Avenue Martin Luther King, 87000 Limoges, France
| | - Isabelle Runge
- Department of Intensive Care Unit, Regional Hospital of Orléans, Avenue de l'Hôpital, 45067 Orléans, France
| | - Achille Kouatchet
- Department of Intensive Care Unit, University Hospital of Angers, Rue Larrey, 49033 Angers, France
| | - Anne Veinstein
- Department of Intensive Care Unit, University Hospital of Poitiers, Rue de la Milétrie, 86000 Poitiers, France
| | - Jérome Tayoro
- Department of Intensive Care Unit, Hospital of Le Mans, Avenue Rubillard, 72037 Le Mans, France
| | - Daniel Villers
- Department of Intensive Care Unit, University Hospital of Nantes, Place Alexis Ricordeau, 44093 Nantes, France
| | - Elisabeth Autret-Leca
- Department of Clinical Pharmacology and Regional Drug Monitoring Centre, University Hospital of Tours, Boulevard Tonnellé, 37044 Tours, France
- François Rabelais University, Rue des Tanneurs, 37041 Tours, France
| |
Collapse
|
33
|
Autret-Leca E. [Drugs news]. Arch Pediatr 2009; 16:478-84. [PMID: 19321323 DOI: 10.1016/j.arcped.2009.02.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2009] [Accepted: 02/04/2009] [Indexed: 10/21/2022]
Affiliation(s)
- E Autret-Leca
- Service de pharmacologie, centre hospitalier régional de Tours, 2, boulevard Tonnelle, 37044 Tours cedex 09, France.
| |
Collapse
|
34
|
Affiliation(s)
- F Beau-Salinas
- Bretonneau Hospital, CHRU of Tours, Regional Centre of Pharmacovigilance, Department of Pharmacology, 37044 Tours Cedex 9, France.
| | | | | | | | | |
Collapse
|
35
|
Jonville-Béra AP, Saissi H, Bensouda-Grimaldi L, Beau-Salinas F, Cissoko H, Giraudeau B, Autret-Leca E. Avoidability of Adverse Drug Reactions Spontaneously Reported to a French Regional Drug Monitoring Centre. Drug Saf 2009; 32:429-40. [DOI: 10.2165/00002018-200932050-00006] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
36
|
Abstract
INTRODUCTION Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy. CASE REPORT We report the case of a 56 year old woman presenting with alveolo-interstitial pneumonia after treatment with Temozolomide. Initially she received induction treatment with Temozolomide and concomitant radiotherapy for bifocal high grade glioblastoma. A month later she received, as scheduled, the first course of Temozolomide maintenance chemotherapy. Grade II dyspnoea developed a few days later. High resolution computed tomography showed alveolo-interstitial opacities with basal predominance, associated with alveolar nodules. Broncho-alveolar lavage showed a lymphocytosis. No bacteria were isolated from microbiological samples. A final diagnosis of drug-induced pneumonia was based on the time sequence and absence of other causes. CONCLUSION There is little literature concerning the pulmonary toxicity of Temozolomide. However, our case report of drug-induced pneumonia and similar observations in the databases of regional pharmacovigilance centres suggest that this side effect should be included in the summary of product characteristics.
Collapse
Affiliation(s)
- L Guilleminault
- Service de Pneumologie, CHU de Tours, Université François Rabelais de Tours, France.
| | | | | | | | | | | | | |
Collapse
|
37
|
Autret-Leca E, Bauer S, Alberti C, Jonville-Béra AP, Aujard Y, Bensouda-Grimaldi L, Baud O. Postnatal glucocorticoids in preterm neonates: use in French neonatal centres in 2006. Arch Dis Child Fetal Neonatal Ed 2008; 93:F398. [PMID: 18723787 DOI: 10.1136/adc.2008.141085] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Jonville-Béra AP, Paroux L, Autret-Leca E. Assessing general practitioners' prescribing behaviour in elderly patients with concealed renal failure. Br J Clin Pharmacol 2008; 65:961-3. [PMID: 18341682 DOI: 10.1111/j.1365-2125.2008.03127.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
39
|
|
40
|
Blasco H, Boisdron-Celle M, Bougnoux P, Calais G, Tournamille JF, Ciccolini J, Autret-Leca E, Le Guellec C. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol 2008; 65:966-70. [PMID: 18294332 DOI: 10.1111/j.1365-2125.2008.03106.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
41
|
Autret-Leca E, Norbert K, Bensouda-Grimaldi L, Jonville-Béra AP, Saliba E, Bentata J, Barthez-Carpentier MA. Le DRESS syndrome, une réaction d'hypersensibilité aux médicaments, qui reste mal connue des pédiatres. Arch Pediatr 2007; 14:1439-41. [DOI: 10.1016/j.arcped.2007.07.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2007] [Accepted: 07/09/2007] [Indexed: 10/22/2022]
|
42
|
Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard CB, Panei P, Autret-Leca E. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2007; 64:311-7. [PMID: 18026941 DOI: 10.1007/s00228-007-0401-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2007] [Accepted: 10/10/2007] [Indexed: 10/22/2022]
Abstract
OBJECTIVE The aim of the study was to describe the prevalence and utilization patterns of methylphenidate (MPH) in children and adolescents in France. METHODS This was a population-based retrospective study in which the cohort consisted of patients for whom data were extracted from the dispensation drug claims database of the national health insurance (NHI) fund for self-employed workers. Annual prevalence of MPH use was evaluated on patients aged 6-18 years who were reimbursed for at least one MPH prescription a year. Between January 2004 and June 2005, features of MPH medication and user profile were described for the "new starters" having a screening period of 1 year without receiving a MPH prescription and a follow-up >or=12 months. Time to interruption of MPH regular use was analysed by Kaplan-Meier survival analysis. Mean duration of exposure to MPH treatment was computed with the 95% confidence interval (CI). RESULTS Annual prevalence of MPH per 1000 persons was 1.1 in 2003, 1.5 in 2004 and 1.8 in 2005 (relative increase of 63.5%). New starters (n = 447) received their first MPH prescription through the hospital (65.1%) or through private practitioners (34.9%). The user profiles were: short (16.6%), occasional (33.8%) and regular (49.6%). Among the new starters, the median time to interruption of MPH regular use was 10.2 months (95% CI: 7.9-12.4). The mean duration of exposure to MPH treatment was: occasional (4.9 months, 95% CI: 4.3-5.5) and regular (25.7 months, 95% CI: 24.6-26.8). CONCLUSION Although there is a low prevalence of MPH use in France, this survey revealed a wide profile of users and heterogeneous use patterns.
Collapse
Affiliation(s)
- Anne-Laure Knellwolf
- Clinical Research Unit, Department of Drug Research and Evaluation, Italian National Institute of Health, viale Regina Elena 299, 00161 Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Affiliation(s)
- E Autret-Leca
- Service de pharmacologie, centre hospitalier régional de Tours, 2, boulevard Tonnelé, 37004 Tours cedex 09, France.
| |
Collapse
|
44
|
Deligne J, Grimaldi L, Jonville-Béra AP, Giraudeau B, Blum-Boisgard C, Autret-Leca E. Antipyretic drug use in children in French office based medical practice. Pharmacoepidemiol Drug Saf 2007; 16:812-7. [PMID: 17546571 DOI: 10.1002/pds.1422] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
PURPOSE To analyse antipyretics (APs) prescriptions profile in children, particularly the frequency of AP combinations. METHODS APs (acetylsalicylic acid, paracetamol, ibuprofen or ketoprofen) prescribed to children below 12 years and refunded by a public health insurer in 2003, throughout France, were examined. RESULTS A total of 513 034 prescriptions were refunded for 240 720 children. The mean number of AP prescriptions per child was the highest in children aged 6 months to 2 years. Paracetamol was the main AP prescribed, but its prescription declined with age, from 90.8% below 3 months old to 57.4% between 6 and 12 years old. Ibuprofen-only prescriptions were rare below 3 months and maximal between 2 and 6 years. The ibuprofen/paracetamol combination was prescribed from 6 months old, and its frequency was maximal between 2 and 6 years old (21.7%). CONCLUSIONS The clear predominance of paracetamol prescriptions suggests that French prescribers are relatively aware of the relative risk-benefit ratio of the different APs. Studies are required to determine if the APs are prescribed to be used alternately or when a monotherapy fails. Guidelines to manage fever in children are needed in France to restrict APs combination to the case of paracetamol failure.
Collapse
Affiliation(s)
- Jean Deligne
- CANAM, Caisse Nationale d'Assurance Maladie des Professions Indépendantes, France
| | | | | | | | | | | |
Collapse
|
45
|
|
46
|
Abstract
OBJECTIVE The main objective of this study was to compare the single-dose efficacy of 15 mg/kg paracetamol (acetaminophen) versus 10 mg/kg ibuprofen in a general practice setting. METHODS Children from the age of 3 months to 12 years with a fever of non-serious origin were randomized to receive either ibuprofen or paracetamol. The first dose was given double-blind, using a double-dummy technique. Tympanic temperature was measured at baseline and over the following 8 hours. The second and subsequent doses were administered open-label for up to 3 days by parents at home. At the end of the double-blind and the open-label periods, parents were asked to subjectively rate the efficacy of the product and state whether they would treat their child with the product again. The primary endpoint of the study was the area under the temperature reduction curve expressed as an absolute difference from baseline, from 0 to 6 hours (AUC(0-6)). Secondary efficacy endpoints included a variety of objective and subjective measures. RESULTS No statistically significant differences in the primary endpoint or any of the objective secondary endpoints were observed. Both agents were equally well tolerated. Compared with parents in the paracetamol group, significantly more parents in the ibuprofen group rated the drug as very efficacious, and reported that they would use the drug again in both the double-blind and open-label phases of the study. CONCLUSIONS Ibuprofen at a dose of 10 mg/kg and paracetamol at a dose of 15 mg/kg have equivalent efficacy and tolerability; parental opinion in favor of ibuprofen could be explained by additional benefits of ibuprofen that were not measured in this trial and helped allay their anxiety over the treatment of their child.
Collapse
|
47
|
Roblot F, Besnier JM, Giraudeau B, Simonnard N, Jonville-Bera AP, Coipeau P, Choutet P, Autret-Leca E, Le Guellec C. Lack of association between rifampicin plasma concentration and treatment-related side effects in osteoarticular infections. Fundam Clin Pharmacol 2007; 21:363-9. [PMID: 17635174 DOI: 10.1111/j.1472-8206.2007.00490.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The aim of this study was to assess the frequency of gastrointestinal side effects (GSE) and hepatotoxicity in patients treated with rifampicin for an osteoarticular infection and to determine if there is an association between rifampicin plasma concentrations and side effects. Rifampicin plasma concentrations were prospectively measured before (trough concentration, C(0)) and 2 +/- 0.5 h (peak concentration, C(2)) after drug intake. The presence of GSE, the alanine transferase (ALT) value, and concomitantly administered medications were recorded on the day rifampicin concentrations were measured. C(0) and C(2) were compared for differences regarding the presence or absence of side effects. Multivariate analysis was performed, with associated medications being taken into account. Seventy C(0) and 57 C(2) values were measured in 46 adults after a median treatment of 8 days (range, 1-179). Wide inter-individual variability was observed for C(0) and C(2). Thirteen (28%) patients reported GSE at least once. When GSE occurred, C(0) (median, 1 mg L(-1); range, 0.1-9.9 mg L(-1)) and C(2) (median, 10.3 mg L(-1); range, 1.8-40.3 mg L(-1)) were similar to C(0) (median, 0.6 mg L(-1); range, 0.1-10.3 mg L(-1)) and C(2) (median, 10.9 mg L(-1); range, 2.9-29.0 mg L(-1)) without GSE. The ALT value was more than normal in only three patients (6.5%) after rifampicin treatment began. The patients received no different associated medications whether or not GSE were present. Multivariate analysis showed no association between rifampicin plasma concentrations and GSE. GSE occur frequently in patients receiving rifampicin for osteoarticular infection but without an association with rifampicin plasma concentrations. Thus, therapeutic drug monitoring of rifampicin is irrelevant in the management of GSE.
Collapse
Affiliation(s)
- France Roblot
- CHRU de Tours, Service des Maladies Infectieuses, 2 boulevard Tonnellé, 37044 Tours Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Autret-Leca E, Bensouda-Grimaldi L, Goldwirt L, Jonville-Béra AP. Anti-inflammatoires non stéroïdiens et analgésie postopératoire: encore des controverses. Arch Pediatr 2007; 14:955-7. [PMID: 17572077 DOI: 10.1016/j.arcped.2007.05.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2007] [Accepted: 05/10/2007] [Indexed: 11/20/2022]
|
49
|
Affiliation(s)
- E Autret-Leca
- Service de pharmacologie, centre hospitalier régional de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 09, France.
| |
Collapse
|
50
|
Abstract
OBJECTIVE The aim was to detect as soon as possible a rare but severe or unexpected adverse effect (AE) of Prevenar vaccine. A pharmacovigilance survey was required by the French drug agency (Afssaps) to the regional pharmacovigilance centre of Tours (France). METHOD Two approaches were used. One based upon systematic reports and the other upon spontaneous reports. Only severe and /or unexpected AEs were recorded. RESULTS During the 19 months of intensive follow up, 24 AEs (8.7 [5-12.7]/100000 vaccinations) reported by 349 participating paediatricians have been analyzed. Prevenar was the only drug taken in 67% of children. AEs were severe (19 cases) or non severe but unexpected (5 cases). AEs were fever above 39 degrees C (10 cases), cutaneous manifestations (6 cases), neurologic manifestations (5 cases), diarrhoea-vomiting (2 cases), and purulent otitis media (1 case). During the 3.5 years of spontaneous reporting, 130 AEs (6 [5-7]/100000 vaccinations) have been reported and analyzed. AEs were severe (107 cases) or non severe but unexpected (23 cases). AEs were mainly: fever above 39 degrees C (17 cases), cutaneous (39 cases), neurologic (34 cases) and haematological (3 cases) manifestations and diarrhoea-vomiting (5 cases). In 3 children local AE limited the walk (5 cases). DISCUSSION Our results are not far from north American data (VAERS) regarding incidence, kind of AEs and severity. Abnormal crying, members hypertonia and vascularitis not yet mentioned in Prevenar SPC need to be added. CONCLUSION Regarding these new data, benefice-risk balance of Prevenar vaccine remains favourable for active immunisation against invasive infections due to pneumococcus in children.
Collapse
Affiliation(s)
- L Bensouda-Grimaldi
- Service de pharmacologie, centre régional de pharmacovigilance et d'information sur le médicament, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 09, France
| | | | | |
Collapse
|